Skip to content

Impact of Vaccination on Th2 Immunity in Infancy

Impact of Vaccination on Th2 Immunity in Infancy

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02213341
Enrollment
77
Registered
2014-08-11
Start date
2015-01-31
Completion date
2016-06-14
Last updated
2019-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Hypersensitivity

Keywords

Milk Allergy, Egg Allergy, Peanut Allergy, Infant Vaccination

Brief summary

The purpose of this study is to assess the responses in the immune system of infants after they receive the vaccine against diphtheria, tetanus, and pertussis (DTaP). The investigators will do this by studying the immune cells and allergy responses in the blood prior to and after receipt of the third DTaP vaccine.

Detailed description

This is a single-site study of infants who are scheduled to receive their third series (\ 6 month) vaccinations, as routine care, to investigate whether the diphtheria, tetanus, and pertussis (DTaP) vaccination has an effect on specific immunoglobulin E (IgE) levels to milk, egg, or peanut. Infants will be assigned to one of two groups depending on the infant's sensitization to milk, egg, and peanut.

Interventions

PROCEDURESkin prick allergen test

To test for hypersensitivity to milk, egg, or peanut

PROCEDUREBlood draw

Sponsors

Consortium of Food Allergy Research
CollaboratorOTHER
National Institute of Allergy and Infectious Diseases (NIAID)
Lead SponsorNIH

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Months to 7 Months
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent from parent/guardian * General good health without other known need for blood draws that would conflict with the study volume requirements * Aged 5 months - 7 months, any race/ethnicity, any gender * Subjects must not have yet received their third DTaP vaccination, which typically is given at 6 months of age. Subjects must have previously received two doses of the DTaP vaccination, at ages 2 months and 4 months * Willingness to return for follow-up testing as defined in the protocol and consent if screening tests indicate eligibility * Group 1 participants must have all of the following: * A negative skin prick test to egg, milk, and peanut * A negative IgE to egg, milk, and peanut * Group 2 participants must have all of the following: * A positive family history of allergic disease * Atopic Dermatitis not requiring prescription medication * A positive IgE to milk, egg, and/or peanut If Group 1 enrollment is completed first, participants must have all of the following to be enrolled in Group 2: * A family history of atopy * Atopic dermatitis not requiring prescription medication If Group 2 enrollment is completed first, participants must have all of the following to be enrolled in Group 1: -No personal or family history of atopic disease

Exclusion criteria

* History of anemia requiring any treatment * Previous allergic reaction to any food, defined as itching, rash, hives, swelling, vomiting, diarrhea, sneezing, rhinorrhea, wheezing, breathing difficulty, or passing out immediately after food ingestion. * Evidence of non-IgE-mediated reaction to milk or soy (i.e. milk/soy protein intolerance) or evidence of food protein induced enterocolitis syndrome (FPIES) * Severe atopic dermatitis (liberally defined as requiring prescription medication) * Unable to obtain serum sample for determination of egg, milk and peanut IgE levels * Use of short-acting anti-histamines (diphenhydramine, etc.) more than one time within 3 days of skin testing or on the day of skin testing * Any history of intravenous or oral steroid medication * Known underlying immune defect/deficiency or bleeding disorder

Design outcomes

Primary

MeasureTime frameDescription
Allergen-specific IgEbaseline and day 28Magnitude of increase of allergen-specific IgE. For each child, the maximum allergen-specific IgE change to milk, egg, or peanut will be considered as the primary endpoint.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026